End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.35 CNY | -18.75% | -.--% | -45.40% |
Jun. 06 | Hainan Poly Pharm's Unit Gets Nod to Market Raw Drug Ingredient Gadoterate Gluconamide | MT |
May. 14 | China Grants Registration Approval for Antibacterial Drug | MT |
Sales 2023 * | 2.05B 283M | Sales 2024 * | 2.38B 328M | Capitalization | 5.54B 764M |
---|---|---|---|---|---|
Net income 2023 * | 473M 65.26M | Net income 2024 * | 550M 75.89M | EV / Sales 2023 * | 2.7 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.33 x |
P/E ratio 2023 * |
11.6
x | P/E ratio 2024 * |
9.96
x | Employees | 1,522 |
Yield 2023 * |
0.65% | Yield 2024 * |
0.81% | Free-Float | 57.56% |
1 day | -18.75% | ||
3 months | -33.67% | ||
6 months | -45.52% | ||
Current year | -45.40% |
Managers | Title | Age | Since |
---|---|---|---|
Min Hua Fan
CEO | Chief Executive Officer | 63 | 92-07-13 |
Tong Ning Luo
DFI | Director of Finance/CFO | 49 | 04-09-30 |
Ji Ping Wang
BRD | Director/Board Member | 52 | 10-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shu Ge Jiao
BRD | Director/Board Member | 58 | 15-05-31 |
Min Hua Fan
CEO | Chief Executive Officer | 63 | 92-07-13 |
Hui Fang Xie
BRD | Director/Board Member | 43 | 04-09-30 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.40% | 764M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.81% | 248B | |
-1.92% | 219B | |
+10.85% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- 300630 Stock